Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 10, 2020 | Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 40,828 | -- | 226,178 | |
| Jan 02, 2021 | Chief Financial Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 15,164 | $23.09 | 226,560 | |
| Jul 08, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 22,052 | $12.28 | 227,314 | |
| Jan 03, 2017 | Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 100,000 | -- | 227,475 | |
| Jan 15, 2021 | Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,731 | -- | 229,499 | |
| Dec 15, 2020 | Chief Financial Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 11,500 | $2.94 | 229,679 | |
| Jun 01, 2015 | Director, Chairman & CEO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 230,000 | -- | 230,000 | |
| Jan 02, 2015 | Director, Chairman & CEO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 230,000 | -- | 230,000 | |
| Jun 26, 2014 | Director, Chairman & CEO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 230,000 | -- | 230,000 | |
| Dec 15, 2020 | Chief Financial Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 7,550 | $4.38 | 237,229 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.